Acusphere AAQS
The The AAQS of Acusphere (ACUS) as of Jul 26, 2026 is 3.
Get this data via API
Financial Data API
AAQS
3
Last updated:
Acusphere has a current AAQS of 3.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Acusphere in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Acusphere in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
Access this data via the Eulerpool API
Acusphere Stock analysis
What does Acusphere do? Acusphere Inc is a US-American company that was founded in 1993. It specializes in the development and marketing of advanced pharmaceuticals and therapeutic platforms in the fields of cardiology and pulmonology. The company is based in Lexington, Massachusetts and currently employs about 30 employees.
The history of Acusphere goes back to the discovery of a new class of pharmaceutical agents, called microspheres. These spherical particles have a diameter of only a few micrometers and can have the ability to bind various therapeutic agents and release them in a targeted manner in the body.
Acusphere has developed several innovative products and technologies based on these microspheres in recent years. One focus of the company is the development of therapies for patients with cardiovascular diseases such as heart failure or coronary artery disease. Another research area of the company is the development of therapies for patients with lung diseases such as COPD or asthma.
The business model of Acusphere is mainly based on the discovery and marketing of new drugs and therapies. In order to achieve these goals, the company works closely with leading scientific institutions and invests a significant portion of its budget in research and development.
Acusphere is divided into several business areas, each of which includes different products and technologies. One of the most important business areas is the development of drugs for the treatment of cardiovascular diseases. An example of this is the drug EchoSphere, which was developed based on microspheres and is able to improve the oxygen supply to the heart muscle.
Another important business area of Acusphere is the development of products for the treatment of lung diseases such as COPD and asthma. For this purpose, the company has developed several new technologies that allow targeted delivery of medication to the lungs and its effects there. One of these technologies is the so-called Solutol technology, which allows medication to be concentrated in the alveoli of the lungs while avoiding unwanted side effects.
In recent years, Acusphere has developed a number of innovative products and technologies that have great market potential due to their high efficacy and tolerability. The company is making every effort to bring these products to the market as quickly as possible and make a significant contribution to improving healthcare. Acusphere is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Acusphere stock
The AAQS of Acusphere is 3 in 2026.
Access this data via the Eulerpool API
Quality — Acusphere
All Key Metrics — Acusphere
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth